Keyword: Foresite Capital Management
The mezzanine round will fund ORIC's lead asset through phase 1b and into phase 2 and move a second program into the clinic.
Now, Insitro is ready to share a little more—starting with a Gilead partnership worth $15 million upfront, but that could total more than $1 billion.
Maze Therapeutics aims to understand how some genes provide protection against disease so that they can be targeted with drugs.
Foresite Capital will focus on backing companies that use data science and machine learning.
The $58 million financing round represents biopharma industry's growing interest in genomics data.
The series B round equips the team that led BioVex to a $1 billion buyout by Amgen to take another crack at developing a cancer-fighting virus.
The series B equips the biotech to take its lead treatment for multidrug-resistant Gram‐negative infections through clinical trials.